Endo Health Solutions was a leading decliner within the health care sector, falling $1.34 (-3.5%) to $36.87 on heavy volume

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Endo Health Solutions ( ENDP) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.3%. By the end of trading, Endo Health Solutions fell $1.34 (-3.5%) to $36.87 on heavy volume. Throughout the day, 4,137,453 shares of Endo Health Solutions exchanged hands as compared to its average daily volume of 2,433,800 shares. The stock ranged in price between $36.64-$38.25 after having opened the day at $36.97 as compared to the previous trading day's close of $38.21. Other companies within the Health Care sector that declined today were: Oculus Innovative ( OCLS), down 16.0%, Synta Pharmaceuticals ( SNTA), down 13.4%, Cormedix ( CRMD), down 12.5% and Coronado Biosciences ( CNDO), down 10.2%.

EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. Endo Health Solutions has a market cap of $4.2 billion and is part of the drugs industry. Shares are up 44.6% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Endo Health Solutions a buy, 3 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Endo Health Solutions as a hold. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, increase in stock price during the past year and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity.